Overcoming hurdles to development of a vaccine against Pneumocystis jirovecii

Beth A. Garvy

doi:10.1128/IAI.00035-17

Overcoming hurdles to development of a vaccine against Pneumocystis jirovecii

Beth A. Garvy

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Abstract

Development of Pneumocystis pneumonia (PCP) is a common problem among immunosuppressed individuals. There are windows of opportunity in which vaccination would be beneficial, but to date, no vaccines have made it to clinical trials. Significant hurdles to vaccine development include host range specificity, making it difficult to translate from animal models to humans. Discovery of crossreactive epitopes is critical to moving vaccine candidates from preclinical animal studies to clinical trials.

Original language	English
Article number	e00035-17
Journal	Infection and Immunity
Volume	85
Issue number	4
DOIs	https://doi.org/10.1128/IAI.00035-17
State	Published - Apr 1 2017

Bibliographical note

Funding Information:
This work was supported in part by grant AI118818 from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, U.S. Department of Health and Human Services.

Publisher Copyright:
© 2017 American Society for Microbiology.

Keywords

Pneumocystis carinii
Vaccines

ASJC Scopus subject areas

Parasitology
Microbiology
Immunology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1128/IAI.00035-17

Cite this

@article{2b9a95e6a3f449acb3fbe84554d32bd9,

title = "Overcoming hurdles to development of a vaccine against Pneumocystis jirovecii",

abstract = "Development of Pneumocystis pneumonia (PCP) is a common problem among immunosuppressed individuals. There are windows of opportunity in which vaccination would be beneficial, but to date, no vaccines have made it to clinical trials. Significant hurdles to vaccine development include host range specificity, making it difficult to translate from animal models to humans. Discovery of crossreactive epitopes is critical to moving vaccine candidates from preclinical animal studies to clinical trials.",

keywords = "Pneumocystis carinii, Vaccines",

author = "Garvy, {Beth A.}",

note = "Funding Information: This work was supported in part by grant AI118818 from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, U.S. Department of Health and Human Services. Publisher Copyright: {\textcopyright} 2017 American Society for Microbiology.",

year = "2017",

month = apr,

day = "1",

doi = "10.1128/IAI.00035-17",

language = "English",

volume = "85",

number = "4",

}

TY - JOUR

T1 - Overcoming hurdles to development of a vaccine against Pneumocystis jirovecii

AU - Garvy, Beth A.

N1 - Funding Information: This work was supported in part by grant AI118818 from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, U.S. Department of Health and Human Services. Publisher Copyright: © 2017 American Society for Microbiology.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Development of Pneumocystis pneumonia (PCP) is a common problem among immunosuppressed individuals. There are windows of opportunity in which vaccination would be beneficial, but to date, no vaccines have made it to clinical trials. Significant hurdles to vaccine development include host range specificity, making it difficult to translate from animal models to humans. Discovery of crossreactive epitopes is critical to moving vaccine candidates from preclinical animal studies to clinical trials.

AB - Development of Pneumocystis pneumonia (PCP) is a common problem among immunosuppressed individuals. There are windows of opportunity in which vaccination would be beneficial, but to date, no vaccines have made it to clinical trials. Significant hurdles to vaccine development include host range specificity, making it difficult to translate from animal models to humans. Discovery of crossreactive epitopes is critical to moving vaccine candidates from preclinical animal studies to clinical trials.

KW - Pneumocystis carinii

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=85016224044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016224044&partnerID=8YFLogxK

U2 - 10.1128/IAI.00035-17

DO - 10.1128/IAI.00035-17

M3 - Comment/debate

C2 - 28115507

AN - SCOPUS:85016224044

VL - 85

IS - 4

M1 - e00035-17

ER -

Overcoming hurdles to development of a vaccine against Pneumocystis jirovecii

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this